These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
127 related items for PubMed ID: 29928988
61. Profile of farletuzumab and its potential in the treatment of solid tumors. Sato S, Itamochi H. Onco Targets Ther; 2016; 9():1181-8. PubMed ID: 27022278 [Abstract] [Full Text] [Related]
62. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Crofts F, Rohatagi S, Pino M, DeLise B, Zhang J, Nguyen M, Guittin P, Barbellion S, Brunel P, Hofmann T, Schmidt J, Wong M, Lockey P, Lerman S, Clark R. Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200 [Abstract] [Full Text] [Related]
63. Fertility and developmental toxicity assessment in rats and rabbits with LY500307, a selective estrogen receptor beta (ERβ) agonist. Hilbish KG, Breslin WJ, Johnson JT, Sloter ED. Birth Defects Res B Dev Reprod Toxicol; 2013 Oct; 98(5):400-15. PubMed ID: 24323950 [Abstract] [Full Text] [Related]
64. Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody. Breslin WJ, Hilbish KG, Martin JA, Halstead CA, Edwards TL. Birth Defects Res B Dev Reprod Toxicol; 2015 Jun; 104(3):117-28. PubMed ID: 26195315 [Abstract] [Full Text] [Related]
73. Male and female fertility assessment in the cynomolgus monkey following administration of ABT-874, a human Anti-IL-12/23p40 monoclonal antibody. Enright BP, Tornesi B, Weinbauer GF, Blaich G. Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):421-30. PubMed ID: 23213064 [Abstract] [Full Text] [Related]
74. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017. Barrow P. Reprod Toxicol; 2018 Sep; 80():117-125. PubMed ID: 29660390 [Abstract] [Full Text] [Related]
75. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jørgensen TK, Hey A, Kragh M. Clin Cancer Res; 2011 Sep 15; 17(18):5962-72. PubMed ID: 21825041 [Abstract] [Full Text] [Related]